ToolGen (199800) Stock Outlook 2026: The CRISPR Patent Moat and the Royalty Timing Problem
ToolGen (KOSDAQ 199800) 2026 stock outlook. A deep qualitative look at its CRISPR gene-editing foundational patent IP, the contested Cas9 priority disputes, the licensing and milestone royalty model, agri and therapeutic pipelines, and how a foreign investor should size and manage a high-risk Korean biotech option.
ToolGen 199800 CRISPR
